What the seller says
A name and printed amount are assertions. They do not establish identity, quantity, purity or sterility.
Compound evidence record · C-009
BPC-157: evidence, product claims, and safety
Marketing has moved much faster than human research. BPC-157 is promoted for tendon, ligament, injury and gut repair, but most published evidence comes from laboratory and animal models.
BPC-157 has extensive preclinical research and only sparse human evidence. No well-established clinical evidence shows that it heals tendon or ligament injuries, speeds recovery, or treats gut disease. Product identity, amount, sterility and safety also remain separate questions that marketing claims cannot answer.
Claim-level evidence
Each marketed outcome needs its own evidence classification.
Tendon and ligament repair
Animal-dominant evidence. Published experiments report effects in rodent injury models. A 2025 systematic review found no robust controlled human evidence showing that BPC-157 improves tendon or ligament healing, function or return to activity.
Faster injury recovery or less pain
Very limited human evidence. Small uncontrolled or retrospective reports cannot separate the molecule’s effect from natural recovery, co-interventions, selection or reporting bias. They cannot establish a reliable effect size or safety profile.
Gut protection or mucosal repair
Mostly preclinical evidence. Animal and laboratory studies support research hypotheses. The FDA’s 2026 assessment identified only limited and poorly reported human material, including a short ulcerative-colitis meeting abstract, and found the evidence insufficient to establish effectiveness.
Safety of a vial sold as BPC-157
Not established by the literature or label. Human safety data are sparse. The FDA has also identified concerns about immunogenicity, peptide-related impurities and inadequate active-ingredient characterisation. A paper about the molecule cannot authenticate a particular product.
What human evidence exists?
A 2025 systematic review located 36 studies published from 1993 to 2024. Almost all were animal studies. Its human material was limited to small reports, including a retrospective knee-pain series, without the controlled design needed to show that BPC-157 caused recovery.
The FDA’s July 2026 briefing reviewed an ulcerative-colitis meeting abstract describing 53 randomised participants and two weeks of treatment. The public record did not provide the full detail expected from a peer-reviewed clinical report. The FDA also noted very small uncontrolled human studies and concluded that the information was insufficient to support effectiveness for the nominated use.
This means the evidence is not literally zero. It is too sparse and methodologically weak to support the broad healing claims used in consumer marketing. See the BPC-157 evidence in full for the records and their limitations.
Research record added 6 September 2026. The 2026 sports-medicine review is considered in our dated injury-recovery literature update. The BPC-157 recovery and pain record also includes the chronic-pain review, with its own scope and access limits.
Why animal repair findings do not settle the human claim
An injury model can test a biological mechanism under controlled conditions. It does not reproduce the varied causes, severity, rehabilitation, co-existing conditions and outcomes seen in people. Species, exposure, timing and outcome measures can also change whether a result transfers.
Clinical usefulness requires more than a signal. Researchers need controlled comparisons, transparent outcome definitions, adequate follow-up and adverse-event collection in the population making the claim. Read how we weigh animal evidence.
The study molecule is not proof about the vial
Four evidence layers must stay separate.
What a document reports
A certificate is useful only when its sample link, methods, results and issuer can be evaluated.
What was measured
A result can support only the attribute, sample and time point it actually examined.
What the molecule may do
Clinical literature cannot verify the contents, manufacturing conditions or handling of a consumer vial.
Use what laboratory tests can and cannot prove and the contamination and mislabelling record before treating any document as whole-product assurance.
UK and sport position
| Question | Evidence-based answer | Where to check |
|---|---|---|
| Is it a UK-authorised medicine? | We found no BPC-157 medicine in the public MHRA product database. That is different from declaring a product safe or lawful for a particular route. | MHRA Products and the UK medicines position |
| Is it prohibited in sport? | Yes. BPC-157 appears in the 2026 Prohibited List under S0, Non-Approved Substances, and is prohibited at all times. | check the current WADA list |
| Does “research use only” settle the position? | No. A label does not override the product’s presentation, supply or intended human use. | the “research use only” label explained |
How we assessed this record
We separated the marketed claim, product documentation, item-specific testing and scientific literature. We prioritised controlled human outcomes over animal mechanisms, full reports over abstracts, and current regulator material over seller summaries. We did not infer an unmeasured product attribute from a purity percentage or transfer findings from a research material to a consumer vial.
Source ledger
Primary and peer-reviewed sources checked on 7 August 2026.
- Systematic review of BPC-157 orthopaedic evidence, 2025 · maps the animal-dominant literature and limited human reports.
- FDA BPC-157 briefing document, July 2026 · substance characterisation, human evidence and safety assessment for the US compounding nomination.
- FDA safety-risk list for compounded bulk substances · current characterisation and immunogenicity concerns.
- World Anti-Doping Agency 2026 Prohibited List · current sport classification.
- MHRA Products database · public UK product-authorisation search.
Follow the adjacent evidence
Questions people ask
Does BPC-157 heal tendons or ligaments?
Animal studies report repair-related findings, but robust controlled human evidence showing better tendon or ligament healing is lacking. Small retrospective reports cannot establish cause, effect size, long-term safety or a dependable return-to-activity benefit.
Is BPC-157 approved in the UK?
We found no BPC-157 medicine in the public MHRA Products database when this record was checked on 7 August 2026. Product authorisation, lawful supply and individual clinical suitability are separate questions.
Is BPC-157 banned by WADA?
Yes. The 2026 World Anti-Doping Agency Prohibited List names BPC-157 under S0, Non-Approved Substances. S0 substances are prohibited at all times, in and out of competition.
Can a certificate prove a BPC-157 vial is safe?
No. A certificate supports only the sample, methods and attributes it covers. Identity or chromatographic purity does not establish amount, sterility, endotoxin, stability, authorised manufacture or clinical suitability.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Claim-level recordDoes BPC-157 heal tendons and ligaments?Read the verdict, confidence, sources and scope limits.Claim-level recordDoes BPC-157 speed injury recovery or reduce pain?Read the verdict, confidence, sources and scope limits.Claim-level recordDoes BPC-157 repair the gut lining in people?Read the verdict, confidence, sources and scope limits.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item C-009, BPC-157: evidence, product claims, and safety was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 5 unique external sources and 16 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Research reference checked and reviewed · 6 September 2026. Scientific review: Eleni Kiromitis. Clinical review: Dr Stavroula Nikitopoulou. The existing evidence verdict is unchanged; earlier sources retain their own check dates.